

July 15, 2025

VIA EMAIL

The Honorable Robert F. Kennedy, Jr.
Secretary
The U.S. Department of Health & Human Services
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201

Re: *Proposed COVID-19 Vaccine Injury Table for Countermeasures Injury Compensation Program*

Dear Secretary Kennedy:

We write on behalf of ICAN to propose the adoption of the attached COVID-19 vaccine injury table for the Countermeasures Injury Compensation Program (“CICP”). The PREP Act provides that “[t]he Secretary **shall** by regulation establish a table identifying covered injuries that shall be presumed to be directly caused by the administration or use of a covered countermeasure.”¹

Your predecessor, Secretary Xavier Becerra, failed to fulfill his duty to establish a COVID-19 vaccine injury table. This has caused a grave injustice to all those injured by this product. We write in the hope you will correct this wrong by adopting the attached proposed table.

It is well established that COVID-19 vaccination causes certain injuries. Even CDC has publicly acknowledged various adverse events associated with the COVID-19 vaccine² and has published studies regarding those adverse events.³ FDA similarly, years ago, required warnings for certain adverse events be added to the patient and provider fact sheets for COVID-19 vaccines.⁴ Despite the availability of robust scientific studies of adverse events following COVID-19 vaccination,⁵ HHS has failed to establish any table injuries for this product.

¹ See 42 U.S.C. § 247d-6e(b)(5)(A) (emphasis added).

² See *CDC Selected Adverse Events Reported After Covid-19 Vaccination*, <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>.

³ See *CDC Covid-19 Vaccine Safety Articles and Studies by Topic*, <https://web.archive.org/web/20240527212225/https://www.cdc.gov/vaccinesafety/research/publications/index.html>.

⁴ Emma Newberger, *FDA Adds Warning About Rare Heart Inflammation to Pfizer, Moderna Covid Vaccines*, CNBC (June 26, 2021), <https://www.cnbc.com/2021/06/26/fda-adds-warning-of-rare-heart-inflammation-to-pfizer-moderna-vaccines.html>.

⁵ Harshini Yaamika et al., *Review of Adverse Events Associated with Covid-19 Vaccines, Highlighting their Frequencies and Reported Cases*, 18(6) J. Taibah Univ. Med. Sci. 1646 (Sept. 2023), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507236/>.

The United States is one of the few developed countries that has not yet added COVID-19 vaccines into its main vaccine injury compensation schemes.⁶ Instead, we require injured individuals to file a claim in the CICIP, a program which fails to meet even the most basic requirements of due process: there are no clear guidelines for establishing causality; the identities of individuals deciding claims are unknown (and therefore it is unclear if they are qualified to decide these claims and/or possess conflicts of interest); there is a strict and excessively short statute of limitations with no discovery rule; and there is no provision for attorneys' fees, nor a route for judicial review, among numerous other flaws.⁷ This means that people who are inexperienced in the legal and medical fields and often seriously injured are forced to put together a demand package meeting complex requirements within an extremely short time frame. The lack of the Injury Table drives this excessive burden of proof even higher, requiring the claimant to affirmatively demonstrate the injury was the direct result of the countermeasure with "compelling, reliable, valid, medical and scientific evidence." 42 C.F.R. § 110.20(c). This is virtually impossible where the countermeasure is a new vaccine and its clinical safety studies have not yet been completed—a state of affairs that existed when each of the current CICIP claimants alleging injury from COVID-19 vaccines filed their requests for benefits.

The CICIP data clearly reflect this hardship on the vaccine injured: compensation rates for CICIP claims currently sit at an abysmal 0.28%.⁸ It is notable that various other countries have implemented strict but at least somewhat reasonable criteria for establishing causality for COVID-19 vaccine-related injuries and have exponentially higher compensation rates than the CICIP.⁹

Given that more than four years have passed since introduction of COVID-19 vaccines in the United States, an injury table is long overdue, and any further delay is inexcusable, prejudicial, and immoral. The United States was at the forefront of COVID-19 vaccine development, was among the first countries to offer COVID-19 vaccines, and it was one of the first high-income countries to mandate them.¹⁰ However, CICIP's shortcomings have caused us to shamefully fail in the duty to caring for those who have been seriously hurt by these products.

To be clear, the creation of an injury table will not cure the myriad defects with CICIP nor does it make right the government's decision to grant immunity to liability to manufacturers; it is, however, the least that can be done for those injured by these products.

⁶ Cho Ryok Kang et al. *COVID-19 Vaccine Injury Compensation Program: Lessons Learned from a Review of 10 Implementing Countries*, 39(13) J. Korean Med. Sci. 121 (Apr. 2024), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004775/>.

⁷ See Verified Complaint, *Smith v. United States*, No. 4:24-cv-00334 (N.D. Tex. Apr. 18, 2024). See also Third Amended Verified Complaint for Declaratory Relief, *Smith v. United States Health Resources & Services Administration*, No. 3:23-CV-01425 (W.D. La., Mar. 17, 2024).

⁸ Countermeasures Injury Compensation Data, <https://www.hrsa.gov/cicp/cicp-data> (showing 39 claims compensated of 13,836 submitted concerning COVID-19).

⁹ See Kang *supra* note 6.

¹⁰ Emily Cameron-Blake et al., *A Panel Dataset of Covid-19 Vaccination Policies in 185 Countries*, 7 Nature Human Behavior 1402 (Aug. 2023), <https://www.nature.com/articles/s41562-023-01615-8>.

We therefore respectfully submit and request adoption of the attached proposed COVID-19 vaccine injury table.

Very truly yours,

A handwritten signature in blue ink, appearing to read 'A. Siri', with a stylized flourish at the end.

Aaron Siri, Esq.
Elizabeth A. Brehm, Esq.
Catherine Cline, Esq.
ebrehm@sirillp.com

Enc: Proposed COVID-19 Vaccine Injury Table
CC: Andrew Downing, Andrew.Downing@hhs.gov

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Abdominal abscess	Case study: 24hr	32
Abdominal pain	Onset: 10-12 days	17 ; 30 ; 31
Abnormal Liver Enzymes	Onset: 6-46 days	33 ; 34
Acute Cholangitis	Onset: 1 day	13 ; 31
Acute Coronary Syndrome	Onset: 6hrs	1 ; 7 ; 35 ; 43
Acute Disseminated Encephalomyelitis (ADEM)	Case study: 12 days Median onset: 14 days	1 ; 2 ; 3 ; 10 ; 15 ; 37
Acute Hemorrhagic Encephalitis (AHEM)	Onset: 1-2 weeks	15 ; 37
Acute Inflammatory Demyelinating Polyneuropathy (AIDP)	Onset: 14-90 days	38 ; 39
Acute Interstitial Nephritis	Onset: 1-82 days	1 ; 41
Acute Kidney Injury	Onset: 1-82 days	13 ; 40
Acute Myeloid Leukemia	Case study: 1 day	42
Acute Necrotizing encephalopathy (ANE)	Case study: 2 days	3 ; 36
Acute Respiratory Distress Syndrome (ARDS)	Case study: hours- 7 days	7 ; 32
Acute Systolic Heart Failure	Onset: 1 day -3wks	44
Acute Tubulointerstitial Nephritis (ATIN)	Onset: 1-82 days	1 ; 40
Adhesive capsulitis (Frozen shoulder)	Onset: 1-4 weeks	8 ; 10 ; 57
Adrenal crisis	Case study: 24hrs	20
Adult-onset Still's disease (AOSD)	Case study: 1 day- 4months	21 ; 25
Affective Disorders	Onset: 0-14 days	18
Alopecia	Onset: 1-3 weeks	24 ; 46
Altered mental status	Case study: 24hr	15
Amyotrophic Lateral Sclerosis (ALS)	Case study: 1 day	27
Anaphylaxis	Onset: 5min	1 ; 5 ; 7 ; 10 ; 14 ; 52 ; 53

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
ANCA-associated vasculitis	Onset: 1-77 days	19 ; 40
Anemia	Case study: 1 day	1
Aneurysm	Case study: same day	48
Angioedema	Onset: 15min- 39hrs	10 ; 14 ; 52
Annular lichen planus	Onset: 48hrs – 10 days	14
Anti-Glutamic Acid Decarboxylase Antibody (GAD-ab)	Onset: 3 days- 8 weeks	49
Anti-nuclear Antibodies (ANA)	Case study: 0-28 reviewed	52
Anti-neutrophil cytoplasmic autoantibody vasculitis	Onset: 1-77 days	1
Antiphospholipid syndrome	Case study: 1 day	50
Aortic dissection	Case study: minutes	35
Aphasia	Case study: 7 days	15 ;
Aplastic anemia	Case study: within 3wks	47
Appendicitis	Onset: 10-12 days	15 ; 17
Arrhythmias	Onset: 1-7 days	1 ; 35 ; 43 ; 45
Arterial Hypertension	Onset: minutes to days	45
Asthma	X	X
Ataxia	Onset: hours +	15 ;
Atopic Dermatitis	Onset 1 day- 4 weeks	14
Atrial Fibrillation	Case report: <24hrs	43
Atrial Flutter	Onset: 1-7 days	58
Atrioventricular (AV) Block	Case study: 24hrs	59
Autoimmune encephalitis	Onset: 1-2 weeks	2 ; 15 ;
Autoimmune hemolytic anemia (AIHA)	Onset: 3-36 days	25

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Autoimmune hepatitis	Onset: 1-53 days	25 ; 33
Autoimmune Thyroiditis	Onset: 1-60 days	60
Behcet's syndrome	X	28 ; 52
Bell's Palsy (Idiopathic facial paralysis) (acute peripheral facial palsy)	Case study: 5hrs Onset: 1-23 days	1 ; 2 ; 3 ; 10 ; 12 ; 52
Benign Fasciculation Syndrome	Case study: 6 days	61
Bone injury (injection)	Onset: <48hrs	56 ; 57
Bowel peritonitis	Case study: 48hrs	62
Brachial plexus injury (PTS)	Onset: 13hrs- 8 weeks	63
Bullous pemphigoid	Onset: 1-60	22
Burning tongue syndrome	Onset: 1-28 days	64
Bursitis (includes Hemorrhagic and Septic)	Onset: minutes-	8 ; 10 ; 56
Capillary leak syndrome		4 ; 6
Cardiac Arrest		1 ; 35 ; 43
Cardiomegaly		35
Cardiomyopathy		1 ; 4 ; 35 ; 44 ; 53
Cellulitis		65
Central Retinal Vein Occlusion		66
Cerebral Vascular Accident (CVA)		X
Cerebral Venous Sinus Thrombosis (CVST)	Onset: 5-30 days	1 ; 2 ; 3 ; 10 ; 35
Chest pain		1 ; 45 ; 53
Chilblains	Case study: 2 days	1 ; 14 ; 50 ; 52
Cholecystitis	Onset: 20-28hr	17
Chronic inflammatory demyelinating polyneuropathy (CIDP)		12 ; 15

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Chronic thrombotic microangiopathy		1
Cochleopathy		3
Cognitive deficits		1 ; 15
Complex Regional pain syndrome		57
Congestive Heart Failure (CHF)		67
Constipation		17 ; 15
COVID 19 infection		68
CSF Antibodies		24
CSF Pleocytosis		24
CSF Protein		24
Cytokine storm		6 ; 7 ; 15 ; 35 ; 43
Death		1 ; 5 ; 7 ; 12 ; 15 ; 26 ; 35
Deep Vein Thrombosis (DVT)		12 ; 43
Depression		18
Dermatomyositis		52
Diabetes mellitus		16 ; 25 ; 49
Diarrhea	Onset: 24hrs	17 ; 15 ; 31
Diverticulitis	Onset: 1 day	17
Dizziness		15 ; 31
Drug-induced interstitial lung disease (DIILD)	Case study: 4 days Median onset: 1-36 days	82 ; 83
Duodenal ulcer perforation		13 ; 31
Dysarthria		15 ; 26
Dysautonomia		69

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Dysphagia		15 ; 26
Dystonia		70
Encephalitis	Median onset: 7-11 days	15
Encephalopathy	Case study: 24hrs	3 ; 4 ; 10 ; 15
Enterocolitis	Onset: 9-15hr	13 ; 17 ; 31
Eosinophilic colitis		17
Epilepsy		2
Epistaxis		13 ; 31
Epstein Barr reactivation (EBV)		71
Erectile dysfunction		X
Erythema/edema	Onset: 1-12 days	1 ; 14
Erythromelalgia		1
Erythema nodosum		14
Fatigue		1 ; 15
Fever		1 ; 15 ; 17 ; 31
Functional Neurological Disorders		3 ; 18 ; 15 ; 61 ; 84
Gait disturbance		15
Gastrointestinal Dysmotility		15
Gastroparesis		72 :
Giant Cell arteritis (GCA)		25
Grave's Disease		17 ; 25 ; 60
Guillain Barre Syndrome (GBS)	Onset: 1-84 days	1 ; 2 ; 5 ; 12 ; 17 ; 15 ; 26
Headache	Onset: 2 hrs	1 ; 2 ; 3 ; 10 ; 12 ; 15 ; 61

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Hemolytic anemia		17
Hemorrhagic stroke		12
Henoch Schoenlein Purpura (HSP)		52
Hepatomegaly		33
Herpes Zoster	Case study: 2 days	1 ; 3 ; 14 ; 19
Hyperactive encephalopathy		2
Hypertension		1 ; 35 ; 43
Hyponatremia		1
Hypophysitis		2
Hypotension		1 ; 6
IgA Nephropathy	Onset: 1-6 weeks	1 ; 25 ; 40 ; 51
IgA Vasculitis		19
Immune complex vasculitis		19
Immunoglobulin nephropathy		1
Immune Thrombocytopenic Purpura (ITP)		35 ; 43
Infertility	Case study: same day	12
Intracerebral hemorrhage (ICH)	Onset: 5-12 days	1 ; 2 ; 3
Ischemic stroke	Case study: 7 days	2 ; 3 ; 10 ; 12
Jaundice		33
Joint pain		1
Kawasaki disease		73
Kounis syndrome		7 ; 53
Leukocytoclastic vasculitis		1 ; 19

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Local injection site reactions		14
Lymphadenopathy		55 ; 82
Lymphocytic vasculitis		19
Maculopapular reactions	Case study: 48hrs	14 ; 19 ; 53
Mast Cell Activation Syndrome (MCAS)		74
Membranous nephropathy		1 ; 25
Menstruation changes		43
Memory loss	Case study: 6 days	1
Minimal change disease (MCD)		1 ; 40
Miscarriage		75
Morbilliform eruption	Onset: 2-7 days	1 ; 14 ; 50
Multiple sclerosis		2 ; 10 ; 52
Myalgia		1 ; 10 ; 15
Myasthenia gravis (MG)		26 ; 52
Myocarditis	Case study: 1 day	1 ; 4 ; 5 ; 7 ; 10 ; 12 ; 17 ; 35
Myocardial infarction		1 ; 4 ; 12 ; 15 ; 35
Myoclonus		3
Myositis	Case study: 2 days	3 ; 76
Nausea		17
Nerve injury		15 ; 26 ; 57
Neuroleptic malignant syndrome (NMS)	Case study: 24hrs	3
Neurological adverse effects		1 ; 15
Neuromyelitis Optica		2

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Neutrophil cytoplasmic autoantibodies		1
Non-Hodgkin Lymphoma		29
Olfactory dysfunction		3
Optic neuritis		3 ; 17 ; 15
Pancreatitis	Onset: 13-28 days	17 ; 30
Paraplegia		15
Paresthesia		10 ; 55 ; 82
Parsonage-Turner Syndrome	Onset: hours- 28 days	3 ; 26 ; 57
Pericarditis		1 ; 5 ; 10 ; 12 ; 35 ; 52
Petechial rash		19
Pityriasis Lichenoid Et Varioliformis Acute (PLEVA)		77
Pityriasis rosea	Case study: 4 days	1 ; 14
Pleural effusion		32
Pneumonia		32
Polymyalgia Rheumatica		10 ; 52
Portal vein thrombosis		33
Postural Orthostatic Tachycardia Syndrome (POTS)		12
Psychosis		18 ; 15
Pulmonary Embolism		1 ; 4 ; 12 ; 35
Pulmonary Hypertension		23
Purpuric macules		1 ; 14 ; 19
Reactive arthritis		78
Respiratory failure		4

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Rhabdomyolysis	Case study: 2 days	1 ; 3
Rheumatoid Arthritis		25 ; 52
Rotator cuff tendinopathy		8 ; 9 ; 15 ; 56
Seizures	Case study: 72hrs	1 ; 3 ; 10 ; 15
Sensorineural hearing loss	Onset: 0-21days	12
Sensory neuropathy		3
Septic Arthritis		56
Shortness of breath		53
SIRVA (Shoulder injury related to vaccine administration)		8 ; 55 ; 82
Small Fiber Neuropathy	Case study: 1 day	2 ; 26 ; 52
Status epilepticus	Case study: 2 days	15
Steven-Johnson syndrome		14
Stiff- person syndrome (SPS)		X
Stroke		35 ; 43
Subarachnoid hemorrhage		3
Supraventricular Tachycardia (SVT)		35
Swelling at injection site		1
Syncope		79
Systemic Lupus erythematosus (SLE)		25 ; 40 ; 50
Tachycardia		1 ; 6 ; 15 ; 35 ; 43
Thrombosis		1 ; 3 ; 5 ; 7 ; 35
Thrombocytopenia		1 ; 5 ; 10 ; 35
Tinnitus		11 ; 12

CICP: COVID-19 VACCINE INJURY TABLE

Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration	Supportive Citations
Tolosa-Hunt Syndrome	Case study: 7 days	2 ; 26
Transverse Myelitis (TM)	Onset: 14-68 days	1 ; 2 ; 3 ; 10 ; 12 ; 15
Trigeminal Neuralgia (TN)		80
Ulcers (oral and genital)		52
Unconsciousness		1
Urinary retention		15 ;
Urticarial rash	Onset: 2-8 days	1 ; 14 ; 19 ; 40
Uveitis	Case study: Few hrs	52
Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT)	Onset: 5-30 days	4 ; 10 ; 14 ; 35 ; 43
Vasculitis		1 ; 19 ; 25 ; 28 ; 50 ; 52
Venous Thromboembolism	Median onset: 8 days	43
Vertigo		11
Visual disturbance		1 ; 61 ; 81
Vomiting		17 ; 33

1. [Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases - PMC](#)
2. [Neurological side effects of SARS-CoV-2 vaccinations](#)
3. [Neurological Complications Following COVID-19 Vaccination - PMC](#)
4. [A Systematic Review Of Autopsy Findings In Deaths After COVID-19 Vaccination - Science, Public Health Policy and the Law](#)
5. [Coronavirus Disease 2019 \(COVID-19\) Vaccine Safety | Vaccine Safety | CDC](#)
6. [Full article: The systemic capillary leak syndrome following COVID-19 vaccine](#)
7. [Cytokine Storms and Anaphylaxis Following COVID-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches - PMC](#)
8. [Shoulder injury related to vaccine administration \(SIRVA\) after COVID-19 vaccination - PMC](#)
9. [Common characteristics of SIRVA following COVID-19 vaccination: a comprehensive systematic review - ScienceDirect](#)
10. [Incidence and management of the main serious adverse events reported after COVID-19 vaccination - Padilla-Flores - 2024 - Pharmacology Research & Perspectives - Wiley Online Library](#)
11. [Audiovestibular adverse events following COVID-19 vaccinations - ScienceDirect](#)
12. [Summary | Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration | The National Academies Press](#)
13. [Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study - PMC](#)
14. [Pearls and pitfalls: Adverse cutaneous reactions after COVID-19 vaccination - PMC](#)
15. [Encephalitis following COVID-19 Vaccination: A Systematic Review - PMC](#)
16. [Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports | BMC Endocrine Disorders | Full Text](#)
17. [Acute abdomen following COVID-19 vaccination: a systematic review - PMC](#)
18. [Psychiatric adverse reactions to COVID-19 vaccines: A rapid review of published case reports - PMC](#)
19. [SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review - PMC](#)
20. [Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency | JCEM Case Reports | Oxford Academic](#)
21. [Adult-onset Still's disease following COVID-19 vaccination - PMC](#)

CICP: COVID-19 VACCINE INJURY TABLE

22. [Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review - PMC](#)
23. [Case Report: Two Case Reports of Pulmonary Hypertension after mRNA COVID-19 Vaccination - PubMed](#)
24. [Alopecia areata following COVID-19 vaccine: a systematic review | European Journal of Medical Research | Full Text](#)
25. [Insights into new-onset autoimmune diseases after COVID-19 vaccination - PMC](#)
26. [Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients | BMC Neurology | Full Text](#)
27. [\(PDF\) A case of rapidly progressive amyotrophic lateral sclerosis associated with SOD1 mutation \(p.D126H variant\) following COVID-19 vaccination](#)
28. [Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study - PMC](#)
29. [Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature - PubMed](#)
30. [Acute abdomen following COVID-19 vaccination: a systematic review - PMC](#)
31. [Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study - PMC](#)
32. [\(PDF\) Empyema with an extensive retroperitoneal abscess after the first dose of the COVID-19 vaccine, a case report](#)
33. [New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review | BMC Gastroenterology | Full Text](#)
34. [Unexplained liver test elevations after SARS-CoV-2 vaccination - PMC](#)
35. [Unraveling Cardiovascular Risks and Benefits of COVID-19 Vaccines: A Systematic Review | Cardiovascular Toxicology](#)
36. [Acute haemorrhagic necrotizing encephalopathy in the setting of SARS-CoV-2 vaccination: a case report and literature review - PMC](#)
37. [Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination - PMC](#)
38. [Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: update of the literature and patient characterization - PubMed](#)
39. [Acute Inflammatory Demyelinating Polyneuropathy Secondary to Moderna COVID Vaccine Dose #2: A Case Report - PM&R Meeting Abstracts](#)
40. [New Onset Biopsy-Proven Nephropathies after COVID Vaccination | American Journal of Nephrology | Karger Publishers](#)
41. [Acute interstitial nephritis after COVID-19 vaccination | BMJ Case Reports](#)
42. [Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report - PMC](#)
43. [Adverse Hematological Effects of COVID-19 Vaccination & Pathomechanisms of Low Acquired Immunity in Patients w/ Hematological Malignancies](#)
44. [VACCINE ASSOCIATED HEART FAILURE | JACC](#)
45. [Cardiac complications of COVID-19 vaccination: now we know more - PMC](#)
46. [New Study Suggests Alopecia After COVID-19 Vaccine Rare but Possible](#)
47. [Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series - PMC](#)
48. [Intracranial aneurysm rupture within three days after receiving mRNA anti-COVID-19 vaccination](#)
49. [Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination](#)
50. [Pfizer–biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity - PMC](#)
51. [COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database - PubMed](#)
52. [Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination](#)
53. [ATAK Complex \(Adrenaline, Takotsubo, Anaphylaxis, and Kounis Hypersensitivity-Associated Coronary Syndrome\) after COVID-19 Vaccination and Review of the Literature - PMC](#)
54. [Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults - ScienceDirect](#)
55. [Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | New England Journal of Medicine](#)
56. [Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration \(SIRVA\) | Skeletal Radiology](#)
57. [Shoulder Injuries and Vaccines - Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration - NCBI Bookshelf](#)
58. [OCCURRENCE OF ATRIAL FIBRILLATION AFTER RECEIVING A SARS- COV-2 VACCINE](#)
59. [Intermittent complete heart block with ventricular standstill after Pfizer COVID-19 booster vaccination: A case report - PMC](#)
60. [Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence - PMC](#)
61. [Benign Fasciculation Syndrome and Migraine Aura without Headache: Possible Rare Side Effects of the BNT162b2 mRNA Vaccine? A Case Report and a Potential Hypothesis - PMC](#)
62. [Pfizer COVID-19 vaccine-induced peritonitis - PMC](#)
63. [A Rare Case of Brachial Plexus Neuropraxia After COVID-19 Vaccination - PMC](#)
64. [Effects of post-COVID-19 vaccination in oral cavity: a systematic review | Evidence-Based Dentistry](#)
65. [COVID-19 vaccine-induced cellulitis and myositis | Cleveland Clinic Journal of Medicine](#)
66. [Risk assessment of retinal vascular occlusion after COVID-19 vaccination | npj Vaccines](#)
67. [Heart Failure With Severely Reduced Ejection Fraction Following Covid-19 Vaccine: A Case Series - Journal of Cardiac Failure](#)
68. [Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression - The Lancet](#)
69. [Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers - PubMed](#)
70. [Dystonia as a complication of COVID-19 vaccinations is not as rare as portrayed - ScienceDirect](#)
71. [Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis - PubMed](#)
72. [Official journal of the American College of Gastroenterology | ACG](#)
73. [Atypical Kawasaki Disease after COVID-19 Vaccination: A New Form of Adverse Event Following Immunization - PubMed](#)
74. [SARS-CoV-2 vaccination complicated by small fiber neuropathy, mast cell activation syndrome, and pericarditis | Clinics](#)
75. [Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion | New England Journal of Medicine](#)
76. [COVID-19 vaccine-induced cellulitis and myositis | Cleveland Clinic Journal of Medicine](#)

CICP: COVID-19 VACCINE INJURY TABLE

77. [Pityriasis lichenoides chronica induced by COVID-19 messenger RNA vaccination](#)
78. [Reactive arthritis after vaccination against SARS-CoV-2: A case series and a mini-review - PubMed](#)
79. [Syncope, paresis and loss of vision after COVID-19 mRNA-based vaccination and SARS-CoV-2 infection | Infection](#)
80. [A case of trigeminal neuralgia developing after a COVID-19 vaccination. - Abstract - Europe PMC](#)
81. [Syncope, paresis and loss of vision after COVID-19 mRNA-based vaccination and SARS-CoV-2 infection | Infection](#)
82. [COVID-19 vaccine induced interstitial lung disease](#)
83. [Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database \(VigiBase\)](#)
84. [Functional disorders as a common motor manifestation of COVID-19 infection or vaccination](#)
85. [After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines](#)

Resources:

[Table 1. Alleged COVID-19 Countermeasure Claims Filed | HRSA](#)

Data as of April 1, 2025

This table displays the alleged countermeasure and alleged injury/death for each COVID-19 countermeasure claim filed as of April 1, 2025. Of the 13,764 COVID-19 countermeasure claims, 10,651 allege injuries/deaths from COVID-19 vaccines and 3,113 allege injuries/deaths from other COVID-19 countermeasures. These 3,113 claims include those where it is unclear upon initial submission of the claim whether the injury/death is alleged from a vaccine or a non-vaccine COVID-19 countermeasure.

[CDC website- vaccine safety, data and additional study links](#)

- Anaphylaxis
- Myocarditis/Pericarditis
- GBS
- Thrombosis/TTS
- Death

[COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network \(GVDN\) cohort study of 99 million vaccinated individuals - ScienceDirect](#)

Safety signals

Neuro:

- GBS
- ADEM
- TM
- Bell's Palsy
- Seizures (generalized and febrile)

Hematologic:

- Thrombocytopenia
- Pulmonary embolism
- CVST
- SVT

Cardiovascular:

- Myocarditis
- Pericarditis

[Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults - ScienceDirect](#)

Serious AESI

Pfizer trial- Table 3

Moderna trial- Table 4

Alphabetical List of AEST's- Pfizer

[\(PDF\) FOIA Release - 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports](#)

[5.3.6-postmarketing-experience.pdf](#)- Pg. 16-25